Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silvanex
- Development stage
- Preclinical
- Lead developer
- Andira Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Silvanex** is Andira Pharmaceuticals' proprietary triple-combination antimicrobial technology comprising silver, cannabichromene, and cannabigerol. It is being developed as a dual-action anti-infective and wound-repair platform for topical treatment of diabetic ulcers and for infection-control medical-device applications including post-surgical wound dressings and IV insertion-site products. Andira reports broad bactericidal and fungicidal activity, including against antimicrobial-resistant pathogens and biofilms, through a microbial cell-wall-targeting mechanism; the company also reports enhanced wound-healing cell viability. The technology remains investigational and includes both drug-product and medical-device candidates.
- Brand names
- Matrix3Matrix-3Matrix 3Silvanex
- Other names
- Silvanex Antimicrobial Technology
02
Targets
Bacterial and fungal cell wall and membrane components
Beyond the preview
Go deeper on Silvanex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silvanex.